Request a free sample report to know exact growth variance and the Y-O-Y growth rate
Herpes Zoster Therapeutics Market Scope |
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 14.67% |
Market growth 2022-2026 |
$ 4.51 billion |
Market structure |
Fragmented |
YoY growth (%) |
10.40 |
Regional analysis |
North America, Europe, Asia, and ROW |
Performing market contribution |
North America at 41% |
Key consumer countries |
US, Germany, China, Canada, and UK |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
Abbott Laboratories, Bausch Health Companies Inc., Zydus Lifesciences Ltd., Cipla Ltd., Eli Lilly and Co., Emcure Pharmaceuticals Ltd., GlaxoSmithKline Plc, Maruho Co. Ltd., Merck and Co. Inc., and Novartis AG |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for the forecast period, |
Customization preview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Herpes Zoster Therapeutics Market 2022-2026: Segmentation
The herpes zoster therapeutics market share growth by the vaccination segment will be significant during the forecast period. Vaccines are among the most important biologic therapies that help in the prevention of various disease outbreaks. The importance of vaccines comes from the fact that they are able to provide active immunization, wherein dead or live microbial antigens are administered to individuals before they are naturally infected by the antigen. After immunization, if the person gets infected by that antigen, there will be sufficient antibodies present in the body, which will rapidly eliminate that antigen. Such effective application of vaccines will positively impact the segment growth during the forecast period.
Request for a FREE sample to gain further insights on the market contribution of various segments
- Geography
- North America
- Europe
- Asia
- ROW
The 41% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for herpes zoster therapeutics market in North America. Market growth in this region will be faster than the growth of the market in ROW.
The sales of drugs and vaccines used in the treatment/prophylaxis of herpes zoster will facilitate the herpes zoster therapeutics market growth in North America over the forecast period.
Request for a FREE sample now! for more insights on the market share & contribution of various regions & segments
Increased Incidence of Herpes Zoster to Drive the Market Growth
Exposure to ultraviolet radiation may suppress cell-mediated immunity, which can be a major factor responsible for the increased incidence of herpes zoster. Additionally, factors such as stress are expected to weaken the immune system of an individual. The weakened immune system further increases the risk of getting herpes zoster and other infectious diseases. Furthermore, tropical climate may be associated with the increasing incidence of shingles. Patients being treated for cancer and people with advanced HIV infection are at a greater risk of developing shingles. Thus, the increased incidence of herpes zoster across the globe is expected to drive the growth of the market during the forecast period.
Weak Pipeline for Herpes Zoster Therapeutics to Challenge the Market Growth
Despite the availability of vaccination for shingles, the worldwide acceptance of the vaccines has been varied across countries. The main reasons for the reduced acceptance of vaccines among patients include the fear of an upward shift in the peak of the age of the infection. Moreover, universal childhood varicella vaccination programs are not mandatory in most countries. Due to these factors, even though the global herpes zoster therapeutics market has huge growth potential, the realizable market for vaccines may remain low. This will make it less attractive for vaccine manufacturers. Thus, the weak pipeline for herpes zoster is expected to hinder the growth of the global herpes zoster therapeutics market during the forecast period.
Download Free sample Report for insights on the Drivers, Trends, and Challenges that will help companies evaluate and develop growth strategies for 2022-2026
Our Herpes Zoster Therapeutics Market Report Covers the Following Areas:
Herpes Zoster Therapeutics Market 2022-2026: Vendor Analysis
The herpes zoster therapeutics market report offers information on several market vendors, including Abbott Laboratories, Bausch Health Companies Inc., Zydus Lifesciences Ltd., Cipla Ltd., Eli Lilly and Co., Emcure Pharmaceuticals Ltd., GlaxoSmithKline Plc, Maruho Co. Ltd., Merck and Co. Inc., and Novartis AG among others.
Moreover, the market is fragmented and the vendors are deploying growth strategies such as focusing on expanding their business activities in developed and rapidly emerging markets by launching products to compete in the market.
Download Our FREE Sample Report to get more vendor insights with product offerings & news
Herpes Zoster Therapeutics Market 2022-2026: Key Highlights
- CAGR of the market during the forecast period 2022-2026
- Detailed information on factors that will assist herpes zoster therapeutics market growth during the next five years
- Estimation of the herpes zoster therapeutics market size and its contribution to the parent market
- Predictions on upcoming trends and changes in consumer behavior
- The growth of the herpes zoster therapeutics market
- Analysis of the market's competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of herpes zoster therapeutics market vendors
Related Reports:
Herpes Treatment Market by Type and Geography - Forecast and Analysis 2021-2025: The herpes treatment market has the potential to grow by USD 723.04 million during 2021-2025, and the market's growth momentum will decelerate at a CAGR of 3.40%. To get more exclusive research insights: Download Our FREE Sample Report
Shingles Vaccine Market by Type and Geography - Forecast and Analysis: The shingles vaccine market size has the potential to grow by USD 1.08 billion during 2020-2024, and the market's growth momentum will accelerate during the forecast period because of the steady increase in year-over-year growth. To get more exclusive research insights: Download Our FREE Sample Report
Table of Contents:
1. Executive Summary
1.1 Market Overview
Exhibit 01: Key Finding 1
Exhibit 02: Key Finding 2
Exhibit 03: Key Finding 3
Exhibit 04: Key Finding 5
Exhibit 05: Key Finding 6
Exhibit 06: Key Finding 7
Exhibit 07: Key Finding 8
2. Market Landscape
2.1 Market ecosystem
Exhibit 08: Parent market
Exhibit 09: Market characteristics
2.2 Value chain analysis
Exhibit 10: Value chain analysis: Pharmaceuticals
3. Market Sizing
3.1 Market segment analysis
Exhibit 11: Market segments
3.2 Market size 2021
3.3 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.4 Market outlook: Forecast for 2021 - 2026
Exhibit 13: Global - Market size and forecast 2021 - 2026 ($ million)
Exhibit 14: Global market: Year-over-year growth 2021 - 2026 (%)
4. Five Forces Analysis
4.1 Five Forces Summary
Exhibit 15: Five forces analysis 2021 & 2026
4.2 Bargaining power of buyers
Exhibit 16: Bargaining power of buyers
4.3 Bargaining power of suppliers
Exhibit 17: Bargaining power of suppliers
4.4 Threat of new entrants
Exhibit 18: Threat of new entrants
4.5 Threat of substitutes
Exhibit 19: Threat of substitutes
4.6 Threat of rivalry
Exhibit 20: Threat of rivalry
4.7 Market condition
Exhibit 21: Market condition - Five forces 2021
5 Market Segmentation by Product
5.1 Market segments
Exhibit 22: Product - Market share 2021-2026 (%)
5.2 Comparison by Product
Exhibit 23: Comparison by Product
5.3 Vaccination - Market size and forecast 2021-2026
Exhibit 24: Vaccination - Market size and forecast 2021-2026 ($ million)
Exhibit 25: Vaccination - Year-over-year growth 2021-2026 (%)
5.4 Drug therapy - Market size and forecast 2021-2026
Exhibit 26: Drug therapy - Market size and forecast 2021-2026 ($ million)
Exhibit 27: Drug therapy - Year-over-year growth 2021-2026 (%)
5.5 Market opportunity by Product
Exhibit 28: Market opportunity by Product
6. Customer landscape
6.1 Overview
Technavio's customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria
Exhibit 29: Customer landscape
7. Geographic Landscape
7.1 Geographic segmentation
Exhibit 30: Market share by geography 2021-2026 (%)
7.2 Geographic comparison
Exhibit 31: Geographic comparison
7.3 North America - Market size and forecast 2021-2026
Exhibit 32: North America - Market size and forecast 2021-2026 ($ million)
Exhibit 33: North America - Year-over-year growth 2021-2026 (%)
7.4 Europe - Market size and forecast 2021-2026
Exhibit 34: Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 35: Europe - Year-over-year growth 2021-2026 (%)
7.5 Asia - Market size and forecast 2021-2026
Exhibit 36: Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 37: Asia - Year-over-year growth 2021-2026 (%)
7.6 ROW - Market size and forecast 2021-2026
Exhibit 38: ROW - Market size and forecast 2021-2026 ($ million)
Exhibit 39: ROW - Year-over-year growth 2021-2026 (%)
7.7 Key leading countries
Exhibit 40: Key leading countries
7.8 Market opportunity by geography
Exhibit 41: Market opportunity by geography
8. Drivers, Challenges, and Trends
8.1 Market drivers
8.1.1 Increased incidence of herpes zoster
8.1.2 Rising geriatric population
8.1.3 Favorable reimbursement policies for medications, including vaccines
8.2 Market challenges
8.2.1 Weak pipeline for herpes zoster therapeutics
8.2.2 High generic influx of generics
8.2.3 Patient propensity toward substitutes
8.2.3 Patient propensity toward substitutes
Exhibit 42: Impact of drivers and challenges
8.3 Market trends
8.3.1 Emerging innovative vaccines for disease management
8.3.2 Vaccination programs and initiatives providing free vaccines
8.3.3 Expanding research
9. Vendor Landscape
9.1 Overview
Exhibit 43: Vendor landscape
The potential for the disruption of the market landscape was moderate in 2020, and its threat is expected to remain unchanged by 2025.
9.2 Landscape disruption
Exhibit 44: Landscape disruption
Exhibit 45: Industry risks
10. Vendor Analysis
10.1 Vendors covered
Exhibit 46: Vendors covered
10.2 Market positioning of vendors
Exhibit 47: Market positioning of vendors
10.3 Abbott Laboratories
Exhibit 48: Abbott Laboratories - Overview
Exhibit 49: Abbott Laboratories - Business segments
Exhibit 50: Abbott Laboratories - Key news
Exhibit 51: Abbott Laboratories - Key offerings
Exhibit 52: Abbott Laboratories - Segment focus
10.4 Akzo Nobel NV
Exhibit 53: Bausch Health Companies Inc. - Overview
Exhibit 54: Bausch Health Companies Inc. - Business segments
Exhibit 55: Bausch Health Companies Inc. - Key offerings
Exhibit 56: Bausch Health Companies Inc. - Segment focus
10.5 Zydus Lifesciences Ltd.
Exhibit 57: Zydus Lifesciences Ltd. - Overview
Exhibit 58: Zydus Lifesciences Ltd. - Business segments
Exhibit 59: Zydus Lifesciences Ltd. - Key offerings
Exhibit 60: Zydus Lifesciences Ltd. - Segment focus
10.6 Cipla Ltd.
Exhibit 61: Cipla Ltd. - Overview
Exhibit 62: Cipla Ltd. - Business segments
Exhibit 63: Cipla Ltd. - Key offerings
Exhibit 64: Cipla Ltd. - Segment focus
10.7 Eli Lilly and Co.
Exhibit 65: Eli Lilly and Co. - Overview
Exhibit 66: Eli Lilly and Co. - Business segments
Exhibit 67: Eli Lilly and Co. - Key offerings
Exhibit 68: Eli Lilly and Co. - Segment focus
10.8 Emcure Pharmaceuticals Ltd.
Exhibit 69: Emcure Pharmaceuticals Ltd. - Overview
Exhibit 70: Emcure Pharmaceuticals Ltd. - Product and service
Exhibit 71: Emcure Pharmaceuticals Ltd. - Key offerings
Exhibit 72: Emcure Pharmaceuticals Ltd. - Segment focus
10.9 GlaxoSmithKline Plc
Exhibit 73: GlaxoSmithKline Plc - Overview
Exhibit 74: GlaxoSmithKline Plc - Business segments
Exhibit 75: GlaxoSmithKline Plc - Key offerings
Exhibit 76: GlaxoSmithKline Plc - Segment focus
10.10 Maruho Co. Ltd.
Exhibit 77: Maruho Co. Ltd. - Overview
Exhibit 78: Maruho Co. Ltd. - Product and service
Exhibit 79: Maruho Co. Ltd. - Key offerings
10.11 Merck and Co. Inc.
Exhibit 80: Merck and Co. Inc. - Overview
Exhibit 81: Merck and Co. Inc. - Business segments
Exhibit 82: Merck and Co. Inc.- Key news
Exhibit 83: Merck and Co. Inc. - Key offerings
Exhibit 84: Merck and Co. Inc. - Segment focus
10.12 Novartis AG
Exhibit 85: Novartis AG - Overview
Exhibit 86: Novartis AG - Business segments
Exhibit 87: Novartis AG - Key offerings
Exhibit 88: Novartis AG - Segment focus
11. Appendix
11.1 Scope of the report
11.1.1 Market definition
11.1.2 Objectives
11.1.3 Notes and Caveats
11.2 Currency conversion rates for US$
Exhibit 89: Currency conversion rates for US$
11.3 Research Methodology
Exhibit 90: Research Methodology
Exhibit 91: Validation techniques employed for market sizing
Exhibit 92: Information sources
11.4 List of abbreviations
Exhibit 93: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article